Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.3K
3.3K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

13.0K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.0K
RNA Splicing01:32

RNA Splicing

60.1K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell and spatial transcriptomics reveal SPRR2A<sup>+</sup> epithelial-MMP1<sup>+</sup> fibroblast interactions as key drivers of Esophageal Squamous Cell Carcinoma progression.

International journal of biological macromolecules·2026
Same author

Regulatory B cell-related gene signature predicts prognosis and immune landscape in head and neck squamous cell carcinoma.

Frontiers in immunology·2026
Same author

A novel immune-related gene signature stratifies prognosis and characterizes the tumor immune microenvironment in head and neck squamous cell carcinoma.

Frontiers in cell and developmental biology·2026
Same author

Investigation of the expression and potential mechanistic role of BYSL in acute myeloid leukemia.

Clinical and experimental medicine·2026
Same author

LncRNA NEAT1 contributes to multiple myeloma progression via upregulating ARPC5 by sponging miR-133a.

Archives of medical science : AMS·2025
Same author

Establishment and validation of a prognostic model for nasopharyngeal carcinoma patients based on partial response rates.

Frontiers in oncology·2025
Same journal

Dehydroleucodine Induces ROS-Mediated Mitochondrial Apoptosis and G2/M Cell Cycle Arrest in Oral Squamous Cell Carcinoma.

Journal of Cancer·2026
Same journal

CellVizio<sup>®</sup> System for Mesothorax Lymphadenopathy Rapid on Site, 18G needle: Pros and Cons.

Journal of Cancer·2026
Same journal

Epidemiological Trends and Shared Molecular Signatures of Pancreatic Ductal Adenocarcinoma and Diabetes: An Integrative Analysis Based on Global Burden of Disease and Gene Expression Omnibus Datasets.

Journal of Cancer·2026
Same journal

Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors.

Journal of Cancer·2026
Same journal

Exosomes in Cancer Biology: Emerging Biomarkers and Therapeutic Targets.

Journal of Cancer·2026
Same journal

<i>GALNT14</i>-rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma.

Journal of Cancer·2026
See all related articles

Related Experiment Video

Updated: Dec 22, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.9K

Aberrant LncRNA Expression in Leukemia.

Jie Gao1, Fujue Wang1, Pengqiang Wu1

  • 1Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.

Journal of Cancer
|May 6, 2020
PubMed
Summary
This summary is machine-generated.

Long noncoding RNAs (lncRNAs) play a crucial role in leukemia development and progression. Research highlights their potential as diagnostic biomarkers and therapeutic targets for this hematopoietic cancer.

Keywords:
expression profilingleukemialong non-coding RNAs (lncRNAs)therapeutic targetstranscription regulation

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.4K

Related Experiment Videos

Last Updated: Dec 22, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.9K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.4K

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Leukemia is a significant hematopoietic malignancy with incompletely understood pathogenesis.
  • Long noncoding RNAs (lncRNAs) are non-protein-coding transcripts involved in gene regulation.
  • Emerging evidence links lncRNAs to various aspects of cancer, including leukemia.

Purpose of the Study:

  • To review the current understanding of lncRNA roles in leukemia.
  • To explore the potential of lncRNAs as diagnostic and prognostic markers.
  • To discuss lncRNAs as therapeutic targets in leukemia treatment.

Main Methods:

  • Literature review of studies on lncRNAs and leukemia.
  • Analysis of research on lncRNA functions in hematopoiesis and carcinogenesis.
  • Synthesis of findings on lncRNA involvement in leukemia pathophysiology.

Main Results:

  • lncRNAs are implicated in gene expression regulation relevant to leukemia.
  • Specific lncRNAs show promise as biomarkers for leukemia diagnosis and prognosis.
  • lncRNAs represent potential novel therapeutic targets for leukemia.

Conclusions:

  • lncRNAs are critical players in leukemia pathogenesis.
  • Further research into lncRNAs can advance leukemia diagnostics and therapeutics.
  • lncRNAs offer new avenues for understanding and treating leukemia.